When categorized by signaling status, low adiponectin signalers had a 6.56-fold increase in breast cancer risk (95% CI, 0.78–54.89), and intermediate adiponectin signalers had a 4.16-fold increase in risk (95% CI, 0.49–35.19) compared to high signalers (P for trend =0.001). This evidence concerns the gene ADIPOQ and breast carcinoma.